From Barrett metaplasia to esophageal adenocarcinoma

The molecular background

Deborah Saraggi, Matteo Fassan, Jan Bornschein, Fabio Farinati, Stefano Realdon, Nicola Valeri, Massimo Rugge

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The molecular landscape of Barrett’s esophagus and Barrett-related neoplastic lesions is still far from being completely elucidated. Both in vitro and in vivo studies pinpointed the pathogenetic role of different morphogenic pathways (the para-homeobox, the Notch and the Sonic Hedgehog families in particular) implicated in the acquisition of the metaplastic phenotype of the esophageal mucosa. On the other hand, the most common genetic alterations observed during Barrett's carcinogenesis include disorders of major regulators of the cell cycle, as well as deregulation of the TGF-β/Smad and receptor tyrosine kinases signalling pathways. Recent comprehensive mutational profiling studies identified that the inactivation of the TP53 and of the SMAD4 tumour suppressor genes occurred in a stage-specific manner, confined to (high grade) dysplastic and neoplastic lesions, respectively. The next step will be the correlation of these findings into multidisciplinary diagnostic approaches integrating endoscopy, histology, molecular profiling and liquid biopsies. This will allow the introduction of innovative strategies for secondary prevention of esophageal adenocarcinoma based on biological rationales, and the implementation of potential novel therapeutic targets.

Original languageEnglish
Pages (from-to)25-32
Number of pages8
JournalHistology and Histopathology
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Barrett Esophagus
Homeobox Genes
Receptor Protein-Tyrosine Kinases
Secondary Prevention
Tumor Suppressor Genes
Endoscopy
Histology
Cell Cycle
Carcinogenesis
Adenocarcinoma
Phenotype
Biopsy
Therapeutics
In Vitro Techniques
Esophageal Mucosa

Keywords

  • Barrett’s esophagus
  • Biomarker
  • MicroRNA
  • Molecular pathology

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Saraggi, D., Fassan, M., Bornschein, J., Farinati, F., Realdon, S., Valeri, N., & Rugge, M. (2016). From Barrett metaplasia to esophageal adenocarcinoma: The molecular background. Histology and Histopathology, 31(1), 25-32. https://doi.org/10.14670/HH-11-659

From Barrett metaplasia to esophageal adenocarcinoma : The molecular background. / Saraggi, Deborah; Fassan, Matteo; Bornschein, Jan; Farinati, Fabio; Realdon, Stefano; Valeri, Nicola; Rugge, Massimo.

In: Histology and Histopathology, Vol. 31, No. 1, 01.01.2016, p. 25-32.

Research output: Contribution to journalArticle

Saraggi, D, Fassan, M, Bornschein, J, Farinati, F, Realdon, S, Valeri, N & Rugge, M 2016, 'From Barrett metaplasia to esophageal adenocarcinoma: The molecular background', Histology and Histopathology, vol. 31, no. 1, pp. 25-32. https://doi.org/10.14670/HH-11-659
Saraggi, Deborah ; Fassan, Matteo ; Bornschein, Jan ; Farinati, Fabio ; Realdon, Stefano ; Valeri, Nicola ; Rugge, Massimo. / From Barrett metaplasia to esophageal adenocarcinoma : The molecular background. In: Histology and Histopathology. 2016 ; Vol. 31, No. 1. pp. 25-32.
@article{1bc7ded65ec149379b37a9dd4c79c0bb,
title = "From Barrett metaplasia to esophageal adenocarcinoma: The molecular background",
abstract = "The molecular landscape of Barrett’s esophagus and Barrett-related neoplastic lesions is still far from being completely elucidated. Both in vitro and in vivo studies pinpointed the pathogenetic role of different morphogenic pathways (the para-homeobox, the Notch and the Sonic Hedgehog families in particular) implicated in the acquisition of the metaplastic phenotype of the esophageal mucosa. On the other hand, the most common genetic alterations observed during Barrett's carcinogenesis include disorders of major regulators of the cell cycle, as well as deregulation of the TGF-β/Smad and receptor tyrosine kinases signalling pathways. Recent comprehensive mutational profiling studies identified that the inactivation of the TP53 and of the SMAD4 tumour suppressor genes occurred in a stage-specific manner, confined to (high grade) dysplastic and neoplastic lesions, respectively. The next step will be the correlation of these findings into multidisciplinary diagnostic approaches integrating endoscopy, histology, molecular profiling and liquid biopsies. This will allow the introduction of innovative strategies for secondary prevention of esophageal adenocarcinoma based on biological rationales, and the implementation of potential novel therapeutic targets.",
keywords = "Barrett’s esophagus, Biomarker, MicroRNA, Molecular pathology",
author = "Deborah Saraggi and Matteo Fassan and Jan Bornschein and Fabio Farinati and Stefano Realdon and Nicola Valeri and Massimo Rugge",
year = "2016",
month = "1",
day = "1",
doi = "10.14670/HH-11-659",
language = "English",
volume = "31",
pages = "25--32",
journal = "Histology and Histopathology",
issn = "0213-3911",
publisher = "Histology and Histopathology",
number = "1",

}

TY - JOUR

T1 - From Barrett metaplasia to esophageal adenocarcinoma

T2 - The molecular background

AU - Saraggi, Deborah

AU - Fassan, Matteo

AU - Bornschein, Jan

AU - Farinati, Fabio

AU - Realdon, Stefano

AU - Valeri, Nicola

AU - Rugge, Massimo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The molecular landscape of Barrett’s esophagus and Barrett-related neoplastic lesions is still far from being completely elucidated. Both in vitro and in vivo studies pinpointed the pathogenetic role of different morphogenic pathways (the para-homeobox, the Notch and the Sonic Hedgehog families in particular) implicated in the acquisition of the metaplastic phenotype of the esophageal mucosa. On the other hand, the most common genetic alterations observed during Barrett's carcinogenesis include disorders of major regulators of the cell cycle, as well as deregulation of the TGF-β/Smad and receptor tyrosine kinases signalling pathways. Recent comprehensive mutational profiling studies identified that the inactivation of the TP53 and of the SMAD4 tumour suppressor genes occurred in a stage-specific manner, confined to (high grade) dysplastic and neoplastic lesions, respectively. The next step will be the correlation of these findings into multidisciplinary diagnostic approaches integrating endoscopy, histology, molecular profiling and liquid biopsies. This will allow the introduction of innovative strategies for secondary prevention of esophageal adenocarcinoma based on biological rationales, and the implementation of potential novel therapeutic targets.

AB - The molecular landscape of Barrett’s esophagus and Barrett-related neoplastic lesions is still far from being completely elucidated. Both in vitro and in vivo studies pinpointed the pathogenetic role of different morphogenic pathways (the para-homeobox, the Notch and the Sonic Hedgehog families in particular) implicated in the acquisition of the metaplastic phenotype of the esophageal mucosa. On the other hand, the most common genetic alterations observed during Barrett's carcinogenesis include disorders of major regulators of the cell cycle, as well as deregulation of the TGF-β/Smad and receptor tyrosine kinases signalling pathways. Recent comprehensive mutational profiling studies identified that the inactivation of the TP53 and of the SMAD4 tumour suppressor genes occurred in a stage-specific manner, confined to (high grade) dysplastic and neoplastic lesions, respectively. The next step will be the correlation of these findings into multidisciplinary diagnostic approaches integrating endoscopy, histology, molecular profiling and liquid biopsies. This will allow the introduction of innovative strategies for secondary prevention of esophageal adenocarcinoma based on biological rationales, and the implementation of potential novel therapeutic targets.

KW - Barrett’s esophagus

KW - Biomarker

KW - MicroRNA

KW - Molecular pathology

UR - http://www.scopus.com/inward/record.url?scp=84949057541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949057541&partnerID=8YFLogxK

U2 - 10.14670/HH-11-659

DO - 10.14670/HH-11-659

M3 - Article

VL - 31

SP - 25

EP - 32

JO - Histology and Histopathology

JF - Histology and Histopathology

SN - 0213-3911

IS - 1

ER -